Evaluation of cognitive impairment in relapsing-remitting multiple sclerosis patients by using the montreal cognitive assessment test

Aim: Evaluating the cognitive functions of patients with relapsing-remitting multiple sclerosis (RRMS) by using the MontrealCognitive Assessment (MoCA) Test.Material and Methods: This cross-sectional study consisted of 28 RRMS patients who were diagnosed based on the revisedMcDonald 2017 criteria and 30 healthy volunteers. The MoCA test and the Expanded Disability Status Scale (EDSS) were applied.Results: The mean age of the RRMS patients was 37.21±5.61, while the mean age of the healthy volunteers was 35.6±10.09(p=0.459). 17 (60.7%) of the RRMS patients were female, 11 (39.3%) were male, while 16 (63.3%) of the control group were female,and 14 (46.7%) were male (p=0.571). The median total MoCA score was 24 (min: 15, max: 30) for the RRMS patients and 27 (min: 19,max: 30) for the healthy volunteers, and the difference was significant (p=0.006). The scores of the RRMS patients were significantlylower in terms of the MoCA sub-dimensions of executive functions, attention, language and delayed recall. There was a negative,medium-level significant correlation between the total MoCA scores and EDSS scores (r: -0.583; p

PDF

___

1. Diaz C, Zarco L, Rivera DM. Highly active multiple sclerosis: An update. Mult Scler Relat Disord 2019;30:215-24.
2. Opara JA, Jaracz K, Brola W. Quality of life in mulptiple sclerosis. J Med Life 2010;3:352-58.
3. Amato MP, Portaccio E, Goretti B, et al. Cognitive impairment in early stages of multiple sclerosis. Eur J Neurol 2010;31:211-4.
4. Ferreira ML. Cognitive deficits in multiple sclerosis: a systematic review. Arq Neuropsiquiatr 2010;68:632- 41.
5. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-9.
6. Zadikoff C, Fox SH, Tang Wai DF, et al. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord 2008;23:297-9.
7. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-173.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
9. Selekler K, Cangöz B, Sait U. Power of discrimination of Montreal Cognitive Assessment (MOCA) Scale in Turkish patients with mild cognitive impairement and Alzheimer’s disease. Turk J Geriatr 2010;13:166-71.
10. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-51.
11. Patti F. Cognitive impairment in multiple sclerosis. Mult Sclerosis J 2009;15:2-8.
12. Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci. 2007;14:919-27.
13. Aksoy S, Timer E, Mumcu S, et al. Screening for Cognitive Impairment in Multiple Sclerosis with MOCA Test. Turk J Neurol 2013;19:52-5.
14. Rinaldi F, Calabrese M, Grossi P, et al. Cortical lesions and cognitive impairment in multiple sclerosis. Neurol Sci 2010;31:235-7.
15. Datta R, Sollee JR, Lavery AM, et al. Effects of optic neuritis, t2 lesions, and microstructural diffusion integrity in the visual pathway on cortical thickness in pediatric onset multiple sclerosis. J Neuroimaging 2019
16. Charvet L, Taub E, Cersosimo B, et al. The Montreal cognitive assessment (MoCA) in multiple sclerosis: Relation to clinical features. J Mult Scler 2015;2:1-6.
17. Şengül HS, Şengül Y, Yücel S, et al. Cognitive impairment in young multiple sclerosis and essential tremor patients: a comparative study. Turk J Neurol 2016;22:109-13.
18. Kalmar JH, Gaudino EA, Moore NB, et al. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology 2008;22:442-9.
19. Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, et al. Cognitive Dysfunctions and Assessments in Multiple Sclerosis. Frontiers Neurol 2019;10:1-9.